Analyst Stock Recommendations For Gaia, Inc. (GAIA), Tabula Rasa HealthCare, Inc. (TRHC)

Gaia, Inc. (NASDAQ:GAIA) tinted loss of -2.37% (-0.3 points) to US$12.35. The volume of 0.09 Million shares climbed down over an trading activity of 110.65 Million shares. EPS ratio determined by looking at last 12 month figures is -1.5. Over the same time span, the stock marked US$22.75 as its best level and the lowest price reached was US$11.32. The corporation has a market cap of US$221.44 Million.

Gaia, Inc. (NASDAQ:GAIA)’s earnings per share has been growing at a -9.8 percent rate over the past 5 year when average revenue increase was noted as -26 percent. The return on equity ratio or ROE stands at -29.9 percent while most common profitability ratio return on investment (ROI) was -24.1 percent. The company’s institutional ownership is monitored at 83.3 percent. The company’s net profit margin has achieved the current level of -70.9 percent and possesses 86.8 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) is worth US$1.47 Billion and has recently fallen -5.2% to US$72.38. The latest exchange of 0.31 Million shares is below its average trading activity of 344.38 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$91.16 while the mean 12-month price target for the shares is US$85.22.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 14.25, and a price to sales ratio of 7.71. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 87.2%, it carries an earnings per share ratio of -1.48.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.9.